國家衛生研究院 NHRI:Item 3990099045/16193

NHRI > Institute of Molecular and Genomic Medicine > Hong-Hsing Liu > Conference Papers/Meeting Abstract > Item 3990099045/16193

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/16193

Title:	Efficacy of probiotics on the cognitive function, sleep efficiency, and antioxidative biomarkers in patients with Alzheimer's disease dementia: A 12-week randomized, double-blind, parallel-group clinical trial
Authors:	Sun, Y;Kuo, YW;Tsai, SY;Lin, JH;Hsu, YC;Chen, JF;Hsia, KC;Ho, HH;Liu, HH;Kua, HC
Contributors:	Institute of Molecular and Genomic Medicine
Abstract:	Introduction: Accumulating evidence shows positive effects of probiotics in modulating the immune system, which may alter neuroinflammatory process implicated in the cognitive decline and sleep disturbance in Alzheimer’s disease dementia (ADD). This study aimed to determine whether probiotics are effective for cognitive function, sleep and oxidative stress in patients with mild to moderate ADD. Materials and methods: In this randomized, double-blind, parallel-group, single-center trial, all participants had clinical diagnosis of ADD with completion of studies on neuroimage, blood tests and mental tests to exclude dementia diseases other than ADD. Only patients with MMSE 10-26 and CDR 0.5-1 were enrolled. These 32 eligible participants were randomly assigned (1:1) to receive standard daily dose of 1×1010 CFU or low dose of 5×107 CFU of multistrain probiotics capsules ( Bifidobacterium breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02 ), for 12 weeks. The primary endpoint was the change of ADAS-Cog score. Secondary outcome measures were the change of MMSE, ADL, CDR, sleep parameters including total sleep time, sleep onset latency and sleep efficiency measured by actigraphy, serum antioxidant and inflammatory biomarkers including superoxide dismutase (SOD), glucose-6-phosphate dehydrogenase (G6PD), malondialdehyde (MDA), cytokines, and brain-derived neurotrophic factor. All the measures were performed during the 2 weeks after intervention compared with the 2-week preintervention phase. The study is registered with ClinicalTrials.gov, NCT05145881. Results: Less cognitive deterioration as less increase of ADAS-Cog score was found in the group with standard dose of probiotics but without statistical significance (standard dose vs low dose, +0.31 vs +0.37, p=0.97). As compared to low dose group, better sleep with increased total sleep time (+9 vs -16, min), less sleep onset latency (+3 vs +9, min) and increased sleep efficiency (-1 vs -2, %) were found in standard dose group but there were still no significant differences. Nevertheless, serum biomarker assay showed significant differences between groups with higher SOD (p=0.04), lower MDA as lower oxidative stress (p= 0.04) and lower IL-1beta (p=0.04) in ADD patients receiving standard dose of probiotics. Conclusions: This study provides evidence that standard dose of multistrain probiotics significantly increased antioxidant levels, decreased oxidative stress and decreased inflammatory biomarkers in ADD as compared to low dose. The effects of probiotics on cognitive function and sleep disturbance need further larger and long-term studies.
Date:	2024-02
Relation:	Sleep Medicine. 2024 Feb;115(Suppl.1):S234.
Link to:	https://doi.org/10.1016/j.sleep.2023.11.645
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1389-9457&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001295366701321
Appears in Collections:	[Hong-Hsing Liu] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI001295366701321.pdf		58Kb	Adobe PDF	10	View/Open

Loading...